AstraZeneca Results Presentation Deck
Oncology
Product Sales ($m)
800
700
600
500
400
300
200
100
0
■EM
☐EROW
■ Europe
■US
Q3
96
67
155
270
Lynparza
3% decrease at CER to $2,070m in 9M 2023
2021
Q4
103
71
161
294
Q1
121
66
160
270
Q2
120
72
169
312
2022
Q3
117
64
164
314
Q4
130
66
162
331
Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
40jj5 CER = constant exchange rates; EM = Emerging Markets; EROW = Established Rest of World.
Collaboration partners: Merck & Co., Inc. (Lynparza).
Q1
137
68
178
268
Q2
2023
142
77
187
311
Q3
131
71
178
322
Lynparza
Collaboration Revenue: $3.8bn recorded cumulative, $3.9bn future potential
Collaboration Revenue ($m)
600
400
200
0
Sales Milestone
I Regulatory Milestone
Q4
2021
400
Q1
175
Q2
2022
Q3
APPENDIX | 9M 2023 Product Performance
75
Q4
105
Q1
Q2
2023
Q3
3View entire presentation